InsiderPulse
Dashboard

RARE

Ultragenyx Pharmaceutical Inc.

Health CareRussell 2000

Ultragenyx Pharmaceutical Inc. insider trading

Ultragenyx Pharmaceutical Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Novato, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent RARE insider transactions

9 insiders traded RARE on the open market between Mar 02, 2026 and Sep 15, 2026 — 17 sales worth $2.8M, of which 9 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$2.8M

9 of 17 on a 10b5-1 plan

Net
−$2.8M
Insiders
9

Open-market purchases (code P) and sales (code S) from Ultragenyx Pharmaceutical Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every RARE Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

RARE insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 10 insiders traded RARE on the open market: 0 purchases and 47 sales worth $14.1M, 19 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 26 sales ($3.7M), by 9 insiders.

QuarterBoughtSold
Q2 2026—−$575K7 sales · 5 on a plan
Q1 2026—−$2.7M13 sales · 5 on a plan
Q4 2025—−$365.3K3 sales · 1 on a plan
Q3 2025—−$80.9K3 sales
Q2 2025—−$118.8K3 sales · 1 on a plan
Q1 2025—−$6.8M11 sales · 2 on a plan
Q4 2024—−$1.3M3 sales · 2 on a plan
Q3 2024—−$2.1M4 sales · 3 on a plan
Largest sale
−$3.1M of RARE by Kakkis Emil D (President & CEO · Director) on Mar 03, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Horn Howard10b5-1

    Chief Financial Officer

    −$36.6K

    Mar 03, 2026

    1,635 sh · $22.40

  • Parschauer Karah Herdman

    EVP and Chief Legal Officer

    −$185.5K

    Mar 02, 2026

    8,135 sh · $22.80

  • Crombez Eric

    EVP and Chief Medical Officer

    −$160.3K

    Mar 02, 2026

    7,029 sh · $22.80

  • Horn Howard10b5-1

    Chief Financial Officer

    −$120.6K

    Mar 02, 2026

    5,290 sh · $22.80

  • Horn Howard10b5-1

    Chief Financial Officer

    −$70.3K

    Mar 02, 2026

    3,119 sh · $22.54

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    −$37.2K

    Mar 02, 2026

    1,632 sh · $22.80

  • Horn Howard10b5-1

    Chief Financial Officer

    −$72.1K

    Feb 02, 2026

    3,061 sh · $23.56

  • Horn Howard10b5-1

    Chief Financial Officer

    −$71.9K

    Jan 02, 2026

    3,150 sh · $22.84

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    −$2.9K

    Dec 29, 2025

    85 sh · $34.38

  • Horn Howard10b5-1

    Chief Financial Officer

    −$112.1K

    Dec 10, 2025

    3,081 sh · $36.38

  • Horn Howard

    Chief Financial Officer

    −$250.3K

    Oct 13, 2025

    7,942 sh · $31.51

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    −$1.9K

    Sep 18, 2025

    64 sh · $29.17

  • Parschauer Karah Herdman

    EVP and Chief Legal Officer

    −$76.4K

    Sep 12, 2025

    2,450 sh · $31.17

  • Huizenga Theodore Alan

    SVP, Chief Accounting Officer

    −$2.6K

    Sep 05, 2025

    84 sh · $31.39

  • Sanders Corazon (Corsee) D.10b5-1

    Director

    −$89.9K

    Jun 20, 2025

    2,405 sh · $37.39

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Ultragenyx Pharmaceutical Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Novato, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001515673

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought RARE

What the stock actually did in the 90 days following each open-market purchase

Don't check RARE — let it ping you

Get told the moment an insider moves on RARE

Pro watches Ultragenyx Pharmaceutical Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add RARE to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track RARE on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read RARE insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

FOLDACADPTCTMEDPDNLIVEEVTEMALKSAPLSARVNBBIOCYTK
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are RARE insiders buying or selling?
Between Mar 02, 2026 and Sep 15, 2026, 9 Ultragenyx Pharmaceutical Inc. insiders made no open-market purchases and 17 sales worth $2.8M, a net sale of $2.8M. 9 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much RARE stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 10 Ultragenyx Pharmaceutical Inc. insiders made no open-market purchases and 47 sales worth $14.1M. 19 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 26 sales ($3.7M). The largest sale was Kakkis Emil D selling $3.1M on Mar 03, 2025.
What was the largest recent RARE insider trade?
Kakkis Emil D (President & CEO · Director) sold $1.2M of RARE stock on Mar 02, 2026 at about $22.80 a share.
When did an insider last buy RARE shares?
No open-market purchase by a Ultragenyx Pharmaceutical Inc. insider appears in the filings from Mar 02, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale.
Where does RARE insider trading data come from?
From the Form 4 filings Ultragenyx Pharmaceutical Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.